1918106-06-5
Chemical Structure
Govitecan
- CAS No.: 1918106-06-5
- Formula:C73H99N11O22
- Molecular Weight:1482.63
InChIKey: WYTMLZHQEXUPEH-HASCFQAKSA-N
SMILES: O=C1N2C(C3C(C2)=C(C4=CC(O)=CC=C4N3)CC)=CC5=C1COC([C@@]5(CC)OC(OCC6=CC=C(C=C6)NC([C@H](CCCCN)NC(COCC(NCCOCCOCCOCCOCCOCCOCCOCCOCCN7C=C(N=N7)CNC(C8CCC(CC8)CN9C(C=CC9=O)=O)=O)=O)=O)=O)=O)=O
Biological Activity: Govitecan is a topoisomerase I inhibitor and also a linker-payload compound for antibody-drug conjugates (ADCs), with SN-38 as its active component. Govitecan serves as the linker-drug moiety of ADCs targeting CDH17-expressing cancer cells. Govitecan acts as the cytotoxic payload component of ADCs targeting Trop-2. Govitecan can be used in research related to colorectal cancer, gastric cancer, pancreatic cancer, liver cancer, metastatic triple-negative breast cancer, and other conditions[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Govitecan | Govitecan is a topoisomerase I inhibitor and also a linker-payload compound for antibody-drug conjugates (ADCs), with SN-38 as its active component. Govitecan serves as the linker-drug moiety of ADCs targeting CDH17-expressing cancer cells. Govitecan acts as the cytotoxic payload component of ADCs targeting Trop-2. Govitecan can be used in research related to colorectal cancer, gastric cancer, pancreatic cancer, liver cancer, metastatic triple-negative breast cancer, and other conditions. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Wu Q, et al. WO 2025/061181 A1. International Application Published under the Patent Cooperation Treaty (PCT). LEPU BIOPHARMA CO., LTD. International Publication Date: 27 March 2025. International Application No.: PCT/CN2024/120196. International Filing Date: 20 September 2024.
- [2]. Bardia A, et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. The New England journal of medicine. 2021 Apr 22;384(16):1529-1541.
